ReviewCureus2025
Oncological and Functional Outcomes After Minimally Invasive Surgery for Mid and Low Rectal Adenocarcinoma: A Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we analyze the oncological and functional outcomes after minimally invasive surgery (laparoscopic and robotic) for mid and low rectal adenocarcinoma. This is a narrative review of articles published from January 2019 to December 2024 in which we analyzed the rate of short-term oncological outcomes (quality of surgical samples), long-term oncological outcomes (recurrence rate, overall survival, and disease-free survival), and functional disorders (urinary, sexual, and bowel function) after minimally invasive surgery. The rates of complete mesorectum are 67.7%-92.8%, the rate of free circumferential resection margin is 94%-98.2%, and the rate of free distal resection margin is 99.4%-100%. The local recurrence rate is 2.3%-7.3%, the overall survival rate is 80%-95.6%, and the disease-free survival rate is 70%-86.4%. The rate of urinary disorders is 25%-26.5%, sexual disorders are 35%-80%, and bowel disorders are 17%-44.6%. This review demonstrates that minimally invasive surgery yields favorable oncological and functional outcomes. The continuous evolution in robotic surgery will increasingly lead to interesting implications for rectal surgery, thanks to less surgical trauma and better intraoperative visualization of nerves.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.